Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Cureus|October 30, 2024
Treatment of Secondary Hemophagocytic Lymphohistiocytosis Associated With Diffuse Large B-cell Lymphoma Using Loncastuximab Tesirine As Lymphoma-Directed TherapyTimothy Schieber, Jordan Snyder, Forat Lutfi
Cureus|January 14, 2025
Pembrolizumab Leads to Complete Response in an HIV Patient With a Solid Tumor and a Cluster of Differentiation 4 (CD4) Count Less Than 100Bryce C Bortka, Kelly Brunk, Chao Huang, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|April 9, 2026
Tolerability and safety of a 3-step or 12-step chemotherapy desensitization protocolElizabeth Rybolt, Colleen Bohnenkamp, Vincent Cascone, et al.
Clinical Breast Cancer|June 9, 2023
Effect of Concurrent Proton Pump Inhibitors With Palbociclib Tablets for Metastatic Breast CancerTimothy Schieber, Samantha Steele, Stephanie Collins, et al.
JTO Clinical and Research Reports|November 17, 2025
Safety, Efficacy, and Central Nervous System Control in Patients with High Baseline Risk Factors Treated with Tarlatamab for SCLC or Extrapulmonary Small Cell CarcinomaSanjana Mullangi, Manidhar Reddy Lekkala, Sarah Blocker, et al.
Experimental Hematology & Oncology|March 13, 2025
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysisTimothy Schieber, Kelly Brunk, Anna Clennon, et al.
Clinical Lung Cancer|February 26, 2026
Outcomes of Concurrent Radiotherapy With Tarlatamab in Extensive-Stage Small Cell Lung Cancer From the DLL3 PanTUMOR DatabaseDiana Kim, Sarah Blocker, Courtney C Cavalieri, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2026
Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practiceSarah Blocker, Diana Kim, Courtney C Cavalieri, et al.
Pageof 1